Skip to main content
Premium Trial:

Request an Annual Quote

PPD Reported Strong Q3 Revenue, Net Profit Growth

NEW YORK, Oct. 16 - PPD said that strong revenue growth in the third quarter surpassed a mild up tick in R&D spending, helping to drive a surge in net profits.

 

For the period ended Sept. 30, PPD said total revenue were $157.3 million, up from $115.8 million one year ago. R&D in the quarter increased to just under $3 million from 1.4 million year over year.

 

As a result, the company said that net profits in the third quarter 2002 climbed to $18.3 million, or $.33 per share, from $11.5 million, or $.22 per share, in the same quarter one year ago.

 

PPD said it had around $147 million in cash and cash equivalents as of Sept. 30.

 

Click here for more information.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more